XF-73 Dermal
Treatment of skin infections from antibiotic-resistant bacteria in wounds/burns and superficial infections
Preclinical/Phase 1Active
Key Facts
Indication
Treatment of skin infections from antibiotic-resistant bacteria in wounds/burns and superficial infections
Phase
Preclinical/Phase 1
Status
Active
Company
About Destiny Pharma
AMR Bio is a UK-based biotech focused on preventing life-threatening infections through its proprietary XF platform of novel antimicrobial compounds. Its lead asset, XF-73 Nasal, has completed Phase 2b trials for preventing post-surgical staphylococcal infections and is being prepared for Phase 3, with a projected blockbuster potential. The company employs a capital-efficient partnership model, aiming to out-license programs after generating proof-of-concept data, and is supported by prestigious grants from entities like the US NIH/NIAID.
View full company profile